Massachusetts-based Moderna said it plans to cut 10% of its global staff as part of its ongoing efforts to reduce annual ...

The layoffs come as Moderna’s cash position has raised worries on Wall Street that the company may need to raise new capital.

The biotech company’s revenue halved in 2024, and it continues to face uncertainty in the vaccine market. Biotech giant ...

Massachusetts-based Moderna, one of the companies at the forefront of developing a vaccine during the COVID pandemic, ...

CEO Stephane Bancel announced on Thursday that the company plans to cut nearly 10% of its global workforce by the end of 2025 ...

As of March 31, Moderna had $5.97 billion in cash and short-term investments, with total debt of $745 million. But the ...

Despite efforts to spare employees by scaling back R&D and reducing operating costs by roughly $1.5 billion over the next two ...

It’s not often that a CEO outright dismisses M&A prospects, but Moderna CEO Stéphane Bancel says the mRNA biotech has enough ...

Moderna has announced that it plans to cut down 10% of its workforce by the end of the year. CEO Stephane Bancel said in a ...

"Moderna sharpens focus on $1.5bn cost cutting plan after 41% revenue slump" was originally created and published by ...

CEO Stéphane Bancel on Friday stated that the company is lowering its annual revenue forecast due to the timing of shipments despite the company’s upbeat second-quarter numbers. The vaccine maker ...

In a memo to employees, Moderna CEO Stephane Bancel said the company expects to have fewer than 5,000 workers by the end of ...